Anne Chiang (@annechiangmd) 's Twitter Profile
Anne Chiang

@annechiangmd

ID: 2355712993

calendar_today22-02-2014 03:28:18

54 Tweet

289 Followers

88 Following

University of Hawaii Cancer Center (@uhcancercenter) 's Twitter Profile Photo

Join lung cancer experts in Honolulu for the 2nd Annual Hawaii Lung this January! They will discuss key aspects of care for patients with early-stage, locally advanced, and metastatic lung cancer. #LungCancer #UHCancerCenter #PER

Join lung cancer experts in Honolulu for the 2nd Annual Hawaii Lung this January! They will discuss key aspects of care for patients with early-stage, locally advanced, and metastatic lung cancer. 

#LungCancer #UHCancerCenter #PER
Yale Cancer Center (@yalecancer) 's Twitter Profile Photo

Join us LIVE Tuesday, March 5 at 5:30pm as Smilow Shares with Primary Care virtual #CME series for PCPs highlights #LungCancerScreening. Presenters: Jill Banatoski, MD; Dr. Justin D. Blasberg; Lynn Tanoue, MD, MBA. ➡️bit.ly/49gSlF8 Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp Yale Thoracic Surgery

Join us LIVE Tuesday, March 5 at 5:30pm as Smilow Shares with Primary Care virtual #CME series for PCPs highlights #LungCancerScreening.
Presenters: Jill Banatoski, MD; <a href="/DrBlasberg/">Dr. Justin D. Blasberg</a>; Lynn Tanoue, MD, MBA.
➡️bit.ly/49gSlF8
<a href="/SmilowCancer/">Smilow Cancer Hospital</a> <a href="/YaleMed/">Yale School of Medicine</a> <a href="/YNHH/">Yale New Haven Hosp</a> <a href="/YaleThoracic/">Yale Thoracic Surgery</a>
Anne Chiang (@annechiangmd) 's Twitter Profile Photo

#ascoadvocacyday: a great day advocating for research funding, reducing chemo drug shortages, & permanent telehealth reimbursement!!

#ascoadvocacyday: a great day advocating for research funding, reducing chemo drug shortages, &amp; permanent telehealth reimbursement!!
Anne Chiang (@annechiangmd) 's Twitter Profile Photo

This drug tarlatamab really works and is a huge step forward for SCLC! Thanks to our patients!! ❤️ nytimes.com/2024/05/16/hea…

AnnabelleGurwitch (@lagurwitch) 's Twitter Profile Photo

Anne Chiang "we need to change our trials to fit the patient, not the other way around." She also spoke of sharing data from a study with a patient. Wow, how many of us have had an onc show us data? Informed patients can make better choices. #ASCO24

<a href="/Annechiangmd/">Anne Chiang</a>  "we need to change our trials to fit the patient, not the other way around."  She also spoke of sharing data from a study with a patient. Wow, how many of us have had an onc show us data? Informed patients can make better choices. #ASCO24
Guilherme S. C. Correia, MD (@guicorreiamd) 's Twitter Profile Photo

-Awesome discussion about advanced lung cancer by Martin Reck Anne Chiang Matthew Gubens ! From IO, to SCLC, and non-EGFR actionable genomic aberrations! *Treatment selection for IO, chemo-IO, and dual-IO *SCLC is not “one size fits all”, this is 🔑 *NGS always! Tissue and 🩸

-Awesome discussion about advanced lung cancer by <a href="/MartinReck2/">Martin Reck</a> <a href="/Annechiangmd/">Anne Chiang</a> <a href="/MattGubensMD/">Matthew Gubens</a> !
From IO, to SCLC, and non-EGFR actionable genomic aberrations!
*Treatment selection for IO, chemo-IO, and dual-IO
*SCLC is not “one size fits all”, this is 🔑 
*NGS always! Tissue and 🩸
Ticiana Batista (Leal) (@lealticiana) 's Twitter Profile Photo

Closing ASCO 2024 with great discussions in this OncLive Peer Exchange on Immunotherapy in SCLC with updates from ASCO 2024 and recent advances with esteemed colleagues. Don’t miss it! Anne Chiang TaritaThomas MD, PhD, MBA Afshin Dowlati OncLive.com

Closing ASCO 2024 with great discussions in this OncLive Peer Exchange on Immunotherapy in SCLC with updates from ASCO 2024 and recent advances with esteemed colleagues. Don’t miss it! <a href="/Annechiangmd/">Anne Chiang</a> <a href="/Tarita_ThomasMD/">TaritaThomas MD, PhD, MBA</a> Afshin Dowlati <a href="/OncLive/">OncLive.com</a>
Yale Cancer Center (@yalecancer) 's Twitter Profile Photo

.Amin Nassar, MD explores treatment options for 1st line treatment of advanced pure large cell neuroendocrine carcinoma #ASCO24 revealing similar outcomes for chemo, IO & chemoIO, questioning the added benefit of chemoIO compared to chemo alone Anne Chiang OncoAlert

.<a href="/AminNassarMD/">Amin Nassar, MD</a> explores treatment options for 1st line treatment of advanced pure large cell neuroendocrine carcinoma #ASCO24 revealing similar outcomes for chemo, IO &amp; chemoIO, questioning the added benefit of chemoIO compared to chemo alone <a href="/Annechiangmd/">Anne Chiang</a> <a href="/OncoAlert/">OncoAlert</a>